Clinical Trial Update: Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 [Phase 2]

View source ↗

Summary

Phase 2 extension study of mogamulizumab (KW-0761) for Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma in patients who relapsed after complete response…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Mogamulizumab (mogamulizumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-12-29